Crohn's Disease study: Ga68-FAPI-46
Official title 68Ga-FAPI-46 PET/CT for Assessing Small Bowel Fibrostenosis in Crohn's Disease
ClinicalTrials.gov ID: NCT07273188
What this study is testing
What is Ga68-FAPI-46?
an investigational PET radiotracer being studied to detect fibrostenosing Crohn's disease in the small bowel is designed to bind fibroblast activation protein (FAP) and highlight areas of fibrosis on PET imaging
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study wants to find out if a new type of imaging scan can detect early signs of scarring in the small intestine before it causes a blockage.
- Who it's for
- The study is looking for adults with Crohn's disease affecting the small intestine, including those with or without known blockages.
- What's involved
- Participants will have a PET/CT scan using a special tracer that highlights scar tissue. They will also have standard scans like CT or MRI to compare the results.
- Time commitment
- The study involves a single visit for the scans, though the exact duration is not specified in the provided text.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Known small bowel Crohn's disease
- Research or clinical MR enterography, or clinical CT enterography, within 3 months.
- Male or female with age greater than 18 years old.
- Diagnosis of Crohn's disease by a gastroenterologist
- Willingness to undergo 68Ga-FAPI-46 PET/CT
You likely can't join if
- Pregnant and/or breast-feeding people.
- Hypersensitivity to any excipients in 68Ga-FAPI-46
See the full eligibility criteria
- Known small bowel Crohn's disease
- Research or clinical MR enterography, or clinical CT enterography, within 3 months.
- Male or female with age greater than 18 years old.
- Diagnosis of Crohn's disease by a gastroenterologist
- Willingness to undergo 68Ga-FAPI-46 PET/CT
- people with the capacity to give informed consent and willingness to provide written consent
- Pregnant and/or breast-feeding people.
- Hypersensitivity to any excipients in 68Ga-FAPI-46
The study team makes the final eligibility decision.
Where it is enrolling
- Rochester, Minnesota, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Rochester, Minnesota, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.